Phase II study evaluating the impact of AXS-05 on smoking behavior.

Trial Profile

Phase II study evaluating the impact of AXS-05 on smoking behavior.

Planning
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs Bupropion/dextromethorphan (Primary)
  • Indications Smoking withdrawal
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Dec 2017 According to a Axsome Therapeutics media release, James M. Davis is the principal investigator for this trial.
    • 21 Dec 2017 New trial record
    • 14 Dec 2017 According to a Axsome Therapeutics media release, this trial is anticipated to initiate in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top